AL-002 is under clinical development by Alzamend Neuro and currently in Phase II for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase II drugs for Dementia Associated With Alzheimer’s Disease have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AL-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AL-002 overview
AL-002 is under development for the treatment of Alzheimer’s disease, mild to moderate dementia of the Alzheimer’s type and neurodegenerative diseases. It is administered through intravenous and intradermal route. The drug candidate comprises of adjuvant-free dendritic cell pulsed with a peptide.
See Also:
Alzamend Neuro overview
Alzamend Neuro is a biotechnology company, based in the US. The company develops and commercializes drugs, treatments and cures for Alzheimer’s disease.
For a complete picture of AL-002’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
